Healthcare / Medical DevicesJakartaID
$118.00
+1.00 (+0.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-2.2B · quality 44.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$485.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
6.6%
↑Gross Margin
38.3%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+24.9%
FCF CAGR
—
FCF margin
-35.6%
FCF / Net income
-5.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $201.31B · net income $14.02B · FCF $-71.59B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $201.31B | $201.31B | $154.79B | $129.10B |
| Net Income | $14.02B | $14.02B | $15.17B | $13.59B |
| EPS | 3.41 | 3.41 | 3.73 | 3.34 |
| Gross Margin | 38.3% | 38.3% | 39.2% | 38.4% |
| Operating Margin | 11.5% | 11.5% | 13.9% | 11.8% |
| Net Margin | 7.0% | 7.0% | 9.8% | 10.5% |
| Balance Sheet | ||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 4.41 | 4.41 | 3.47 | 3.96 |
| Cash Flow | ||||
| Free Cash Flow | $-71.59B | $-71.59B | $-2.16B | $3.28B |
| Returns | ||||
| ROE | 6.6% | 6.6% | 16.3% | 17.4% |
| Growth & Yield | ||||
| Revenue Growth | 30.0% | 30.0% | 19.9% | — |
| EPS Growth | -8.7% | -8.7% | 11.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
45.4%
EPS terminal req.
$10.47
Spread vs growth
-54.0%
5Y implied EPS CAGR
30.0%
EPS terminal req.
$12.67
Spread vs growth
-38.7%
10Y implied EPS CAGR
19.6%
EPS terminal req.
$20.40
Spread vs growth
-28.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.4%
Start / end P/E
46.1x → 34.6x
EPS bridge
3.73 → 3.41
Residual
+2.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.